Author(s): Galuppo R, Ramaiah D, Ponte OM, Gedaly R
Abstract Share this page
Abstract Numerous signaling pathways, such as Ras/Raf/MAPK, have been implicated in hepatic carcinogenesis. There are at least 35 combination therapy studies for advanced stage hepatocellular carcinoma (HCC) ongoing, and numerous reagents are being tested targeting novel signaling cascades. The management of HCC has changed substantially in recent times, and the successful development of sorafenib has prompted further expansion on molecular targeted therapies to potentially inhibit different pathways in hepatocarcinogenesis.
This article was published in Dig Dis Sci
and referenced in Journal of Stem Cell Research & Therapy